[Analytical Biochemistry 500 \(2016\) 21](http://dx.doi.org/10.1016/j.ab.2016.01.023)-[23](http://dx.doi.org/10.1016/j.ab.2016.01.023)

Contents lists available at ScienceDirect

# Analytical Biochemistry

journal home page: www.elsevier.com/locate/ $\gamma$ 

# Notes & Tips Interpolation method for accurate affinity ranking of arrayed ligand-analyte interactions



Analytical **Riochemistry** 

Richard B.M. Schasfoort <sup>a, b, \*</sup>, Kiki C. Andree <sup>a</sup>, Niels van der Velde <sup>b</sup>, Alex van der Kooi <sup>b</sup>, Ivan Stojanović <sup>a</sup>, Leon W.M.M. Terstappen <sup>a</sup>

a Medical Cell Biophysics Group, MIRA Institute, University of Twente, 7500 AB Enschede, The Netherlands **b** IBIS Technologies, 7521 PR Enschede, The Netherlands

### article info

Article history: Received 27 October 2015 Received in revised form 28 January 2016 Accepted 29 January 2016 Available online 13 February 2016

Keywords: Biosensor Label free Kinetics Affinity SPR imaging

### **ABSTRACT**

The values of the affinity constants ( $k_d$ ,  $k_a$ , and  $K_D$ ) that are determined by label-free interaction analysis methods are affected by the ligand density. This article outlines a surface plasmon resonance (SPR) imaging method that yields high-throughput globally fitted affinity ranking values using a 96-plex array. A kinetic titration experiment without a regeneration step has been applied for various coupled antibodies binding to a single antigen. Globally fitted rate ( $k_d$  and  $k_a$ ) and dissociation equilibrium ( $K_D$ ) constants for various ligand densities and analyte concentrations are exponentially interpolated to the  $K_D$ at  $R_{\text{max}} = 100 \text{ RU}$  response level ( $K_{\text{D}}^{\text{R100}}$ ).

© 2016 Elsevier Inc. All rights reserved.

For multiple applications, the quality of binding, expressed as the dissociation equilibrium constant  $(K_D)$ , is of great importance. The  $K_D$  value (M, mol/L) in a 1:1 Langmuir model is the analyte concentration at which in equilibrium 50% of the ligand molecules are specifically bound with analyte molecules. Because the  $K_D$  is used for the determination of the effective dosage levels of biomolecules that are applied as drugs, the determined  $K_D$  should reflect the  $K_D$  in solution. However, the constants that are derived from current immobilized ligand-based assays are affected by the immobilized state of the ligand [\[1\]](#page-2-0). This causes the determined apparent constants to deviate from the true "solution" constants due to interfering effects that result from the immobilization of the ligand [\[2\].](#page-2-0) These interfering effects include rebinding effects, mass transport limitation, nonspecific binding, and deviation from the 1:1 model binding [\[3\].](#page-2-0) The higher the ligand density, the more pronounced these interfering effects become, and it is generally accepted that the ligand density should be applied just above the limit of detection of the biosensor instrument [\[4\].](#page-2-0) The same holds

Corresponding author.

E-mail address: [r.b.m.schasfoort@utwente.nl](mailto:r.b.m.schasfoort@utwente.nl) (R.B.M. Schasfoort).

for the analyte concentration; interfering effects will occur when multiple analyte molecules compete for interaction with a single immobilized ligand molecule.

The IBIS MX96 instrument (IBIS Technologies, Enschede, The Netherlands) applies a valve-less consecutive injection of samples [\[5\]](#page-2-0). "Back-and-forth" flow-based fluidics enables unlimited interaction times using only a 100-ul sample that can be recovered. Furthermore, the MX96 applies in the dissociation phase so-called co-pumping to keep the concentration of dissociating analyte zero to reduce rebinding effects. The continuous flow microspotter (CFM; Wasatch Microfluidics, Salt Lake City, UT, USA) enables highreliability printing of ligand molecules under flow conditions [\[6\].](#page-2-0) SensEye sensors (gel-type E2S, Ssens, Enschede, The Netherlands) using preactivated surface chemistry were applied for printing an array of monoclonal antibodies in a ligand density gradient  $(3 \times$  dilution series). The instrument enables multiplex (up to 96 spots) kinetic analysis of interactions using "kinetic titration" without a regeneration step. The latter can be used for capture surfaces (e.g., anti-IgG or anti-tag SensEye) and can be applied to test supernatants directly from crude cultivation broths. The 1:1 Langmuir interaction model is applied in Scrubber2 software (BioLogic Software, Campbell, Australia) by global analysis, which has become a global standard for surface plasmon resonance (SPR) users (e.g., Biacore). Scrubber2 has been adapted for the IBIS



Abbreviations used: SPR, surface plasmon resonance; EpCAM, epithelial cell adhesion molecule.

<span id="page-1-0"></span>

Fig.1. Serial view of the rEpCAM ranking experiment over 48 spots consisting of concatenated injections of rEpCAM (concentrations from 0.5 to 32 nM as indicated) without regeneration. In total, 6 spots per antibody  $\times$  8 Abs resulted in 48  $\times$  7  $=$  336 sensorgrams. Top left: Results in tile view are shown for the 8 different monoclonal antibodies (mAbs) of the injections in overlay per spotted antibody (auto-scaled). The  $R_{\text{max}}$  values are shown per spot in the inserted tiled overlay. The sensorgrams in overlay are globally fitted (red lines in the tiled overlay) using the floating align point fitting procedure in Scrubber2 software. (For interpretation of the reference to color in this figure legend, the reader is referred to the Web version of this article.)

MX96 to calculate the affinity constants from the sensorgrams generated on 96 spots simultaneously and to globally fit all of these 96 interaction data at once.

A so-called  $K_{\rm D}^{\rm \, RO}$  method for the determination of affinity constants was published in 2011  $[1,2]$ , where the contribution of interfering effects is minimized or theoretically zeroed, so that the constants are a better estimate of the true constants of biomolecular interactions in solution. This method is based on the extrapolation of the number of immobilized ligands and analyte molecules to zero, thereby mimicking the interaction in which only one ligand and one analyte molecule are involved, enabling a true 1:1 binding model with not any interfering effect theoretically.

Recognized practical effects are additional ligand immobilization artifacts and heterogeneity of surface binding sites. The method will not compensate for this, and the alternative route is by capturing ligands followed by the target interaction. When a harsh regeneration step is included, the  $R_{\text{max}}$  value will decrease after the subsequent injections of the analyte concentrations and can again affect the kinetic affinity constants. Preferably any regeneration step of the surface should be avoided, and this is achieved using kinetic titration [\[7\]](#page-2-0).

As already indicated, the calculation of the "true" affinity equilibrium constant will become more reliable at lower densities, preferably at a "density" of only a single immobilized ligand molecule acting as a free ligand  $[1,2]$ . Then the contribution of the interfering effects will be zero and will no longer influence the rate and affinity equilibrium constants. Practically, this condition cannot be measured, and the more the ligand density is decreased, the more noisy and less reliable the sensorgrams become. In addition, the quality of fits to noisy curves cannot be judged adequately. It should be noted that immobilization artifacts and heterogeneity of surface binding sites should be prevented, for instance, by oriented capturing of the ligands by applying high-affinity anti-ligand antibodies or using tag-anti-tag interactions.

As proof of principle for interpolating the affinity values to a fixed  $R_{\text{max}}$  value, an experimental ranking test of eight monoclonal antibodies directed against the epithelial cell adhesion molecule (active human EpCAM protein fragment, ab155712, Abcam, Cambridge, UK) was performed. The monoclonal antibodies were HO-3 (Trion Research, Planegg, Germany); EpAb3-5, EpAb1-3, EpAb5-4, and OC9-1 (BioMab, Taipei, Taiwan); VU1D9 (kind gift from Immunicon, Huntingdon Valley, PA, USA); 323/A3 (Pierce cat. no. MA5-12436, Waltham, MA, USA); and SPM134 (Abnova cat. no. MAB12106, Taipei, Taiwan)  $[8-12]$  $[8-12]$ . Because the antibodies were not characterized for regeneration conditions, it is preferable to run a kinetic titration experiment where the 54-kDa EpCAM protein fragment was injected starting with a low concentration of 0.5 nM and ending with the highest concentration of 32 nM. Recently, the analysis of such a kinetic titration experiment with a "floating align point fitting" was embedded in the analysis software for 96-plex interaction analysis. Floating align point fitting means that the subsequent injections of the antigen will be fitted without having the align point equal to the injection time point. During the measurement, the antigen interaction will generate an increasing signal, and each new baseline level in the kinetic titration is the result of the accumulated analyte bound to the ligand molecules. So, the align point that is used for the fit calculations is not equal to the injection time zero but rather is always earlier in the concatenated series. The amount of immobilized protein will cause a shift of the SPR dip as measured by the  $R_{LL}$  value (response of local ligand density) that can be considered as the total protein density per spot, whereas the amount of functional ligand is related to the fitted  $R_{\text{max}}$ 

<span id="page-2-0"></span>

**Fig.2.** Equilibrium dissociation constant K<sub>D</sub> (y-axis) as a function of R<sub>max</sub> (x-axis) of<br>rEpCAM to antibodies EpAb3-5, HO-3, VU1D9, SPM134, Clone 323/A3, OC-9-1, EpAB5-4, and EpAB1-3. Each point is the result of global fitting of 6 injections of the kinetic titration experiment. An exponential fit to  $R_{\text{max}} = 100 \text{ RU}$  was applied for the different ligand density spots.

Table 1 Ranking of affinities of the tested anti-EpCAM antibody clones.

	$k_a$ (s <sup>-1</sup> M <sup>-1</sup> )	$k_{d}$ (s <sup>-1</sup> )	$K_{D}$ (M) $R_{\text{max}} = 100$	$K_D(M)$ $R_{\text{max}}=0$
EpAB3-5	$3.1E + 0.5$	1.1E-05	2.6E-11	1.6E-11
$HO-3$	$1.5E + 0.5$	5.9E-06	$4.0E - 11$	$2.1E-11$
VU1D9	$3.1E + 0.5$	8.2E-05	$2.7E-10$	$2.3E-10$
<b>SPM134</b>	$2.6E + 0.5$	9.3E-05	$3.5E-10$	3.9E-10
323/A3	$2.9E + 0.5$	1.7E-04	5.8E-10	$5.4E-10$
$OC-9-1$	$2.6E + 0.5$	1.9E-04	7.5E-10	6.8E-10
EpAB5-4	$2.5E + 0.5$	2.5E-04	1.0E-09	$9.3E - 10$
EpAB1-3	$2.4E + 0.5$	2.5E-04	1.0E-09	9.0E-10
M <sub>137</sub> <sup>a</sup>	$1.6E + 0.5$	4.3E-04	2.8E-09	3.9E-09

<sup>a</sup> Similar determined anti-EpCAM antibody, but fit results are not shown in this Notes & Tips article.

value. Streamlining and selecting relevant data is carried out using the tile plots in SPRintX and Scrubber2 (top left of [Fig. 1](#page-1-0) for 8 spots only).

Injection of a very low antigen concentration, followed by subsequent injections of higher concentrations of the antigen, was performed (concatenated steps by factor 2).

This Notes and Tips article presents the results obtained from an affinity ranking experiment of a single antigen, EpCAM protein fragment (MW  $=$  54 kDa), toward a panel of eight antibodies. Affinity ranking information was obtained by injections of the various antigen concentrations over the high-affinity coupled antibodies without a regeneration step. This kinetic titration method with global fits to the on and off rates for various levels of  $R_{\text{max}}$  showed a significant improvement in reliability when interpolation to  $R_{\text{max}}$  = fixed value is applied. Although theoretically correct, exponential extrapolation to  $R_{\text{max}} = 0$  may lead practically to deviated ranking values when different ranges of  $R_{\text{max}}$  are measured. Extrapolation to  $R_{\text{max}} = 0$  of these different ranges will result in less comparable ranking values, and the lower values contribute greatly to how the exponential extrapolation intersects the y-axis at  $R_{\text{max}} = 0$ . In general, practical ranking of many antibodies simultaneously can be performed when the  $R_{\text{max}}$  ranges of all these antibodies overlap, as is the case with  $R_{\text{max}} = 100$  RU. Then, an  $R_{\text{max}} =$  fixed value can be chosen so that these values can be better ranked with respect to each other and  $R_{\text{max}}$  values lower than 20 RU can be discarded (Fig. 2) (Table 1).

Because the ligand density of an antibody captured to the sensor surface is tuned in Biacore instruments to obtain affinity values at  $R_{\text{max}} = 50$  to 100, these values are considered to be reliable. In SPR imaging instruments, the not-tunable range of ligand densities after off-line spotting can be used to calculate the accurate ranking affinity value of multiple antibodies by interpolating to  $R_{\text{max}}$  = fixed. A rule of thumb regarding low ligand densities but acceptable noise levels using SPR imaging instruments is to interpolate various ligand densities to a fixed value of  $R_{\text{max}} \sim 100 \text{ RU}$ . Furthermore, it is important that the functional concentration, as applied in the fitting routine, is determined accurately for calculation of the absolute affinity values of  $K_D$  and  $k_a$ . The calibrationfree concentration analysis (CFCA) method recently introduced by Karlsson and Roos [13] further improves the accuracy of the kinetic values. However, ranking values (with respect to each other) can be determined without knowing the exact functional analyte concentrations. Thus, the best practical ranking affinity values for comparing many antibodies with the target can be obtained by interpolating the globally fitted affinity values to  $R_{\text{max}} = 100 \text{ RU}$ .

- [1] [W. de Lau, N. Barker, T.Y. Low, B.-K. Koo, V.S.W. Li, H. Teunissen, P. Kujala,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref1) [A. Haegebarth, P.J. Peters, M. van de Wetering, D.E. Stange, J. van Es,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref1) [D. Guardavaccaro, R.B.M. Schasfoort, Y. Mohri, K. Nishimori, S. Mohammed,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref1) [A.J.R. Heck, H. Clevers, Lgr5 homologs associate with Wnt receptors and](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref1) mediate R-spondin signalling, Nature  $\overline{476}$  (2011) 293-[297](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref1).
- [2] [R.B.M. Schasfoort, W. de Lau, A. van der Kooi, H. Clevers, G.H.M. Engbers,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref2) [Method for estimating the single molecular af](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref2)finity, Anal. Biochem. 421 (2012) [794](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref2)-[796](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref2).
- [3] [P. Schuck, H. Zhao, The role of mass transport limitation and surface hetero](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref3)[geneity in the biophysical characterization of macromolecular binding pro](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref3)[cesses by SPR biosensing, Methods Mol. Biol. 627 \(2010\) 15](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref3)-[54.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref3)
- [4] [D.G. Myszka, X. He, M. Dembo, T.A. Morton, B. Goldstein, Extending the range](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref4) [of rate constants available from BIACORE: interpreting mass transport](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref4)influenced binding data, Biophys. J. 75 (1998)  $583-594$  $583-594$ .
- [5] [A.M.C. Lokate, J.B. Beusink, G.A.J. Besselink, G.J.M. Pruijn, R.B.M. Schasfoort,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref5) [Biomolecular interaction monitoring of autoantibodies by scanning SPR](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref5) [microarray imaging, J. Am. Chem. Soc. 129 \(2007\) 14013](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref5)-[14018.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref5)
- [6] [S. Natarajan, P.S. Katsamba, A. Miles, J. Eckman, G.A. Papalia, R.L. Rich,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref6) [B.K. Gale, D.G. Myszka, Continuous-](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref6)flow microfluidic printing of proteins for [array-based applications including surface plasmon resonance imaging, Anal.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref6) [Biochem. 373 \(2008\) 141](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref6)-[146.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref6)
- [7] [R. Karlsson, P.S. Katsamba, H. Nordin, E. Pol, D.G. Myszka, Analyzing a kinetic](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref7) titration series using affi[nity biosensors, Anal. Biochem. 349 \(2006\) 136](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref7)-[147](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref7).
- [8] P. Ruf, O. Gires, M. Jäger, K. Fellinger, J. Atz, H. Lindhofer, Characterisation of the new EpCAM-specifi[c antibody HO-3: implications for trifunctional anti](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref8)[body immunotherapy of cancer, Br. J. Cancer 97 \(2007\) 315](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref8)-[321](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref8).
- [9] [M.Y. Liao, J.K. Lai, M.Y. Kuo, R.M. Lu, C.W. Lin, P.C. Cheng, K.H. Liang, H.C. Wu,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref9) [An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer, Onco](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref9)[target 6 \(2015\) 24947](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref9)-[24968.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref9)
- [10] [C.G. Rao, D. Chianese, G.V. Doyle, M.C. Miller, T. Russell, R.A. Sanders Jr.,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref10) [L.W. Terstappen, Expression of epithelial cell adhesion molecule in carcinoma](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref10) [cells present in blood and primary and metastatic tumors, Int. J. Oncol. 27](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref10)  $(2005)$  49 $-57$  $-57$ .
- [11] [L. De Leij, W. Helrich, R. Stein, M.J. Mattes, SCLC](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref11)-[cluster-2 antibodies detect](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref11) [the pancarcinoma/epithelial glycoprotein EGP-2, Int. J. Cancer Suppl. 8 \(1994\)](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref11)  $60 - 63$  $60 - 63$ .
- [12] [V.K. Langmuir, H.L. Mendonca, D.V. Woo, Comparisons between two mono](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref12)[clonal antibodies that bind to the same antigen but have differing af](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref12)finities: [uptake kinetics and 125I-antibody therapy ef](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref12)ficacy in multicell spheroids, [Cancer Res. 52 \(1992\) 4728](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref12)-[4734](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref12).
- [13] [R. Karlsson, H. Roos, Method of Determining Active Concentration by](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref13) [Calibration-free Analysis, U.S. patent application US20140141529, May 22,](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref13) [2014.](http://refhub.elsevier.com/S0003-2697(16)00047-6/sref13)